Realities of Newer β‐Blockers for the Management of Hypertension
Population
Patients with cardiovascular conditions including hypertension, heart failure, primary treatment of…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support evaluation of newer beta-blockers in hypertension; leaves open confirmation versus traditional agents in RCTs.
Structured PICO
P
Population
Patients with cardiovascular conditions including hypertension, heart failure, primary treatment of myocardial infarction (MI), and secondary prevention of ischemic cardiac events
I
Intervention
Newer beta-blockers (labetalol, carvedilol, nebivolol)
Newer beta-blockers with vasodilatory and antioxidant properties may offer improved tolerability and efficacy in managing hypertension and cardiovascular disease compared to older agents.
Cite This Study
Manrique et al. (2009) studied this question.